Incyte reported strong third-quarter results with significant revenue growth driven by its product portfolio, particularly Jakafi and the new Niktimvo launch. The company is raising its full-year net product revenue guidance, reflecting positive commercial execution and demand. Strategic pipeline prioritization is underway, focusing on high-value, differentiated programs.
Total revenues increased 20% year-over-year to $1.37 billion.
positiveTotal net product revenues increased 19% year-over-year to $1.15 billion.
positiveJakafi net product revenue increased 7% year-over-year to $791 million, driven by a 10% increase in paid demand.
positiveOpzelura net product revenue increased 35% year-over-year to $188 million.
positiveNiktimvo net product revenue increased 27% sequentially to $46 million, showing strong uptake post-launch.
positiveRaised full-year 2025 net product revenue guidance to $4.23 - $4.32 billion.
positiveGAAP operating income increased 204% year-over-year to $443.5 million.
positiveGAAP net income increased significantly year-over-year to $424.2 million.
positiveGAAP diluted EPS increased to $2.11 from $0.54 in the prior year period.
positiveCash, cash equivalents and marketable securities increased to $2.9 billion from $2.2 billion.
positiveGAAP R&D expenses decreased 12% year-over-year to $506.6 million, primarily due to a $100 million milestone payment in Q3 2024. Excluding upfront and milestone payments, R&D expenses increased 7%.
attentionGAAP cost of product revenues increased 15% year-over-year to $99.0 million, driven by revenue growth and Niktimvo profit share.
attentionThe company has paused further development of INCA034460 (anti-CD122) and INCB57643 (BET inhibitor) programs, as well as povorcitinib in chronic spontaneous urticaria (CSU).
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.